GO:0010804 negative regulation of tumor necrosis factor-mediated signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0010804 describes any process that decreases the rate or extent of the tumor necrosis factor (TNF)-mediated signaling pathway, a central inflammatory and cell-survival cascade.
• Negative regulation of TNF signaling is essential for limiting excessive inflammation, preventing tissue damage, and maintaining immune homeostasis.
• Key negative regulators include phosphatases such as SHP-1 and DUSP4, which directly dephosphorylate or inactivate components of the TNF-NF-kB and MAPK arms.
• Dysregulation of this process is linked to inflammatory diseases, cancer, and steroid-induced necrosis of the femoral head.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable precise dissection of negative regulators in TNF signaling.
• EDITGENE provides end-to-end CRISPR services, including library screening and bioinformatics, to accelerate research on GO:0010804-related genes.
Description
The tumor necrosis factor (TNF)-mediated signaling pathway is a master regulator of inflammation, cell survival, and apoptosis. It is initiated by TNF binding to its cell surface receptors, leading to activation of NF-kB, MAP kinases, and downstream transcriptional programs. Unchecked TNF signaling can cause chronic inflammation and tissue destruction, so cells employ multiple negative feedback mechanisms to dampen the pathway. GO:0010804, negative regulation of tumor necrosis factor-mediated signaling pathway, captures these counter-regulatory processes that decrease the rate or extent of TNF signaling. Understanding this GO term is critical for researchers studying inflammatory diseases, cancer, and immune cell biology. This article integrates authoritative QuickGO annotation with real PubMed literature to provide a research-grade overview of the mechanisms, key genes, and experimental models used to study GO:0010804.
negative regulation of tumor necrosis factor-mediated signaling pathway At A Glance
| GO ID | GO:0010804 |
|---|---|
| GO term | negative regulation of tumor necrosis factor-mediated signaling pathway |
| Ontology | biological_process |
| Synonym | negative regulation of TNF-mediated signaling pathway; negative regulation of TNF signaling; negative regulation of tumor necrosis factor-mediated signalling pathway |
| Major function | Dampening TNF-induced NF-kB and MAPK signaling to prevent excessive inflammation and cell death |
| Key regulators | SHP-1, DUSP4, PTEN, calcineurin-Rcan1, and other phosphatases or inhibitory proteins |
| Associated diseases | Inflammatory diseases, cancer, steroid-induced necrosis of the femoral head, endotoxic shock |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, RNA-seq, proteomics, and bioinformatics |
What Is GO:0010804?
GO:0010804 is a biological process term defined as any process that decreases the rate or extent of the tumor necrosis factor-mediated signaling pathway. The TNF-mediated signaling pathway itself is the series of molecular signals generated as a consequence of TNF binding to a cell surface receptor. In practice, negative regulation of TNF signaling includes mechanisms such as dephosphorylation of signaling intermediates, degradation of pathway components, induction of inhibitory proteins, and feedback inhibition of NF-kB or MAPK activation.
Why Is negative regulation of tumor necrosis factor-mediated signaling pathway Important in Cell Biology?
Negative regulation of TNF-mediated signaling is a fundamental brake on inflammation and cell death. Without it, TNF signaling can become chronic and destructive, contributing to autoimmune diseases, cancer progression, and tissue necrosis. This GO term is therefore central to understanding how cells balance pro-inflammatory and pro-survival signals, and it offers therapeutic targets for modulating TNF responses in disease.
• Prevents excessive inflammation by limiting TNF-induced NF-kB and MAPK activation.
• Protects endothelial cells from TNF-mediated apoptosis and growth suppression.
• Modulates immune cell infiltration and cytokine production in inflammatory diseases.
• Influences cancer cell survival and response to targeted therapies such as EGFR inhibitors.
• Regulates mast cell activation through calcineurin-Rcan1 interactions.
• Contributes to the pathogenesis of steroid-induced necrosis of the femoral head.
• Provides targets for anti-inflammatory drug development, as shown by phenylmethimazole in endotoxic shock.
• Helps maintain vascular homeostasis by modulating VEGF and growth factor signaling.
• Is essential for preventing autoimmunity and chronic tissue damage.
• Offers a rich area for CRISPR-based functional genomics and drug discovery.
What Happens During negative regulation of tumor necrosis factor-mediated signaling pathway?
Initiation of TNF signaling and the need for negative regulation
In simple terms: TNF binds to its receptor and turns on inflammatory signals, but the cell needs brakes to stop the response from going out of control.
TNF binding to its cell surface receptor triggers a cascade that activates NF-kB, JNK, and p38 MAPK, leading to gene expression changes that promote inflammation and cell survival. Negative regulation of this pathway is initiated when cells sense prolonged or excessive TNF stimulation and engage feedback inhibitors. For example, TNF-mediated suppression of dual-specificity phosphatase 4 (DUSP4) is part of a crosstalk between NF-kB and MAPK that regulates endothelial cell survival. Similarly, TNF-alpha inhibits growth factor-mediated cell proliferation through SHP-1 activation in endothelial cells, illustrating an early negative feedback mechanism.
Dephosphorylation of key signaling intermediates
In simple terms: Enzymes called phosphatases remove phosphate groups from signaling proteins, turning off the TNF signal.
Protein phosphatases such as SHP-1 and DUSP4 are central negative regulators of TNF signaling. SHP-1 activation by TNF-alpha inhibits growth factor-mediated cell proliferation, demonstrating its role in dampening mitogenic signals. DUSP4, a dual-specificity phosphatase, is suppressed by TNF-alpha, and this suppression is linked to NF-kB and MAPK crosstalk that affects endothelial cell survival. These phosphatases act by dephosphorylating receptor-proximal kinases or downstream transcription factors, thereby reducing the rate or extent of TNF-mediated signaling.
Inhibition of NF-kB and MAPK arms
In simple terms: The TNF pathway splits into NF-kB and MAPK branches; negative regulators can block either branch to reduce inflammation.
TNF signaling bifurcates into NF-kB and MAPK (JNK, p38) arms, and negative regulation can target either branch. Kishore et al. showed that TNF-mediated E2F1 suppression in endothelial cells differentially requires JNK and p38 MAPK, indicating that negative regulators may selectively inhibit one arm. DUSP4 suppression by TNF-alpha modulates the balance between NF-kB and MAPK, influencing endothelial cell survival. Thus, negative regulation of GO:0010804 often involves cross-inhibition between these branches to fine-tune the overall response.
Feedback inhibition by PTEN and lipid phosphatases
In simple terms: PTEN is a lipid phosphatase that can indirectly dampen TNF signaling by altering survival and angiogenic signals.
PTEN modulates vascular endothelial growth factor (VEGF)-mediated signaling and angiogenic effects, which intersect with TNF signaling in endothelial cells. Although PTEN is not a direct TNF pathway component, its ability to dephosphorylate phosphatidylinositol (3,4,5)-trisphosphate affects survival pathways that crosstalk with TNF-induced NF-kB activation. This illustrates how negative regulation of TNF signaling can be achieved indirectly through modulation of shared survival kinases.
Calcineurin-Rcan1 and immune cell modulation
In simple terms: Calcineurin and Rcan1 interact to regulate mast cell activation, which can influence TNF production and signaling.
Wu et al. demonstrated that calcineurin-Rcan1 interaction contributes to stem cell factor-mediated mast cell activation. Mast cells are major sources of TNF, and their activation state can affect TNF-mediated signaling in surrounding tissues. Negative regulation of TNF signaling may therefore involve calcineurin-Rcan1-dependent modulation of mast cell responses, indirectly limiting TNF availability and downstream pathway activity.
Pharmacological and experimental modulation
In simple terms: Drugs like phenylmethimazole can boost negative regulation of TNF signaling to protect against endotoxic shock.
Benavides et al. showed that phenylmethimazole inhibits production of proinflammatory mediators and is protective in an experimental model of endotoxic shock. This compound likely enhances negative regulation of TNF-mediated signaling, reducing the damaging effects of excessive TNF. Such pharmacological tools are valuable for validating the role of GO:0010804 in disease models and for identifying new therapeutic strategies.
Key Genes Involved in GO:0010804 negative regulation of tumor necrosis factor-mediated signaling pathway
The following genes and proteins are experimentally implicated in negative regulation of TNF-mediated signaling, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SHP-1 (PTPN6) | Protein tyrosine phosphatase that inhibits growth factor and TNF-mediated proliferation signals | Target for studying endothelial cell growth suppression by TNF |
| DUSP4 | Dual-specificity phosphatase suppressed by TNF-alpha; modulates NF-kB and MAPK crosstalk | Key node in endothelial cell survival and inflammation |
| PTEN | Lipid phosphatase that modulates VEGF and survival signaling intersecting with TNF | Studied in angiogenesis and crosstalk with TNF pathways |
| RCAN1 | Calcineurin-interacting protein involved in mast cell activation | Potential regulator of TNF production in mast cells |
| E2F1 | Transcription factor suppressed by TNF via JNK and p38 MAPK | Readout for TNF-mediated signaling in endothelial cells |
| JNK | Stress-activated MAP kinase mediating TNF-induced E2F1 suppression | Target for dissecting negative feedback in TNF signaling |
| p38 MAPK | Stress kinase required for TNF-mediated E2F1 suppression | Component of negative regulation crosstalk |
| NF-kB | Transcription factor activated by TNF; subject to negative feedback | Central node in TNF signaling and its regulation |
| EGFR | Receptor tyrosine kinase whose signaling is inhibited by TNF in some contexts | Model for TNF-mediated negative regulation of growth factor signaling |
| VEGF | Growth factor whose signaling is modulated by PTEN and intersects with TNF | Studied in angiogenesis and endothelial survival |
| Calcineurin | Phosphatase that interacts with Rcan1 in mast cells | Regulator of immune cell activation and TNF production |
| TNF-alpha | Cytokine that initiates the signaling pathway and is subject to negative feedback | Central ligand for studying GO:0010804 |
| Phenylmethimazole (drug) | Inhibits proinflammatory mediators and protects in endotoxic shock | Pharmacological tool to enhance negative regulation |
| Gefitinib/Cetuximab | EGFR inhibitors that modulate growth factor signaling | Used to study TNF crosstalk with EGFR in uveal melanoma |
| Steroid-induced necrosis genes | Differentially expressed genes in femoral head necrosis | Potential links to TNF negative regulation in bone disease |
How Is negative regulation of tumor necrosis factor-mediated signaling pathway Regulated?
Negative regulation of TNF-mediated signaling is itself tightly regulated. DUSP4 suppression by TNF-alpha involves crosstalk between NF-kB and MAPK, creating a feedback loop that adjusts the strength and duration of the signal. SHP-1 activation provides another layer of control by inhibiting growth factor-mediated proliferation in endothelial cells. PTEN modulates survival signals that intersect with TNF pathways, indirectly influencing the extent of TNF signaling. Calcineurin-Rcan1 interactions in mast cells can regulate TNF production, thereby affecting pathway activation. Pharmacological agents such as phenylmethimazole can enhance negative regulation, reducing proinflammatory mediator production in endotoxic shock. Together, these mechanisms ensure that TNF signaling is balanced to avoid excessive inflammation while preserving host defense.
negative regulation of tumor necrosis factor-mediated signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SHP-1 (PTPN6) | Endothelial dysfunction and inflammation | Knockout endothelial cells; TNF stimulation assays |
| DUSP4 | Endothelial cell survival and inflammation | Overexpression and knockout in endothelial cells |
| PTEN | Cancer and angiogenesis | PTEN knockout cancer cell lines; VEGF/TNF crosstalk |
| RCAN1 | Mast cell activation disorders | Knockout mast cells; calcineurin interaction studies |
| TNF-alpha | Endotoxic shock and inflammatory diseases | Mouse endotoxic shock model; phenylmethimazole treatment |
Inflammatory and autoimmune diseases
Dysregulated TNF signaling is a hallmark of chronic inflammatory diseases. Negative regulators such as SHP-1 and DUSP4 help restrain TNF-induced NF-kB and MAPK activation, and their dysfunction can lead to excessive inflammation. In endotoxic shock, pharmacological enhancement of negative regulation by phenylmethimazole reduces proinflammatory mediators and protects against lethal inflammation. Thus, GO:0010804 is a key determinant of inflammatory disease severity.
Cancer and tumor microenvironment
TNF can promote tumor cell survival or death depending on context, and negative regulation of its signaling influences cancer progression. In uveal melanoma, EGFR expression and signaling are modulated by TNF, and inhibitors like Gefitinib and Cetuximab trigger antibody-dependent cellular cytotoxicity. PTEN, a negative regulator of survival signaling, is frequently mutated in cancers and modulates VEGF and TNF crosstalk. Therefore, GO:0010804-related genes are relevant to cancer biology and targeted therapy.
Steroid-induced necrosis of the femoral head
Ren et al. identified differential gene expression and immune cell infiltration in patients with steroid-induced necrosis of the femoral head, highlighting inflammatory pathways including TNF signaling. Negative regulation of TNF signaling may protect against bone destruction in this condition, making GO:0010804 a potential therapeutic target.
Mast cell-associated disorders
Calcineurin-Rcan1 interaction contributes to stem cell factor-mediated mast cell activation, which can influence TNF release and downstream signaling. Dysregulation of this interaction may contribute to mast cell-driven inflammatory diseases, linking GO:0010804 to immune cell modulation.
From negative regulation of tumor necrosis factor-mediated signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SHP-1 negatively regulate TNF-induced proliferation arrest? | SHP-1 knockout endothelial cells |
| How does DUSP4 suppression affect endothelial survival? | DUSP4 overexpression and knockout in endothelial cells |
| What is the role of PTEN in TNF-VEGF crosstalk? | PTEN knockout cancer cell lines |
| Does Rcan1 modulate mast cell TNF production? | Rcan1 knockout mast cells |
| Can phenylmethimazole enhance negative regulation of TNF signaling? | Mouse endotoxic shock model |
| What genes are differentially expressed in steroid-induced necrosis? | Patient samples and immune infiltration analysis |
How to Study the negative regulation of tumor necrosis factor-mediated signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function effects on TNF signaling | Validate negative regulators like SHP-1 |
| Point mutation | Specific residue contributions to inhibitory activity | Dissect phosphatase catalytic domains |
| Knock-in tagging | Protein localization and interaction dynamics | Track DUSP4 or PTEN during TNF stimulation |
| Overexpression | Gain-of-function suppression of TNF signaling | Test DUSP4 or PTEN inhibitory capacity |
| RNA-seq | Transcriptional changes upon TNF stimulation | Identify feedback genes and pathways |
| Proteomics | Phosphorylation and protein abundance changes | Map signaling nodes in TNF pathway |
| Pharmacological assay | Effect of drugs on TNF-mediated inflammation | Test phenylmethimazole in endotoxic shock |
CRISPR knockout and point mutation
CRISPR-Cas9 knockout of candidate negative regulators such as SHP-1 or DUSP4 allows researchers to test whether loss of function enhances TNF-mediated signaling. Point mutations can be introduced to ablate specific phosphatase activity or phosphorylation sites, providing mechanistic insights.
Overexpression and knock-in models
Overexpression of negative regulators like DUSP4 or PTEN can suppress TNF-induced NF-kB and MAPK activation, validating their inhibitory role. Knock-in of tagged versions enables tracking of protein localization and interactions during TNF stimulation.
Transcriptomics and proteomics
RNA-seq and proteomics can identify global changes in gene expression and protein phosphorylation upon TNF stimulation in cells with or without negative regulators. Differential gene expression analysis in patient samples has revealed immune cell infiltration linked to TNF pathways.
Pharmacological and functional assays
Compounds like phenylmethimazole can be used to modulate negative regulation and assess effects on proinflammatory mediator production in endotoxic shock models. Functional assays such as proliferation, apoptosis, and cytokine secretion measure the outcome of TNF signaling.
How CRISPR Can Be Used to Study GO:0010804 negative regulation of tumor necrosis factor-mediated signaling pathway
Knockout
CRISPR knockout of genes such as SHP-1 or DUSP4 can reveal their role in negative regulation of TNF signaling. For example, SHP-1 knockout endothelial cells would be expected to show enhanced TNF-induced growth suppression. DUSP4 knockout may exacerbate NF-kB and MAPK activation, affecting cell survival.
Point Mutation
Introducing point mutations in phosphatase catalytic domains or phosphorylation sites can dissect the precise molecular mechanisms by which SHP-1 or DUSP4 inhibit TNF signaling. Such models help distinguish between catalytic activity and scaffolding functions.
Knock-in
Knock-in of fluorescent or epitope tags into endogenous loci of negative regulators allows real-time imaging and interaction studies during TNF stimulation. This approach preserves physiological expression levels and regulatory context.
Overexpression
Overexpression of negative regulators like PTEN or DUSP4 can suppress TNF-induced NF-kB and MAPK activation, providing gain-of-function evidence for their inhibitory role. This is useful for validating therapeutic targets.
How EDITGENE Supports negative regulation of tumor necrosis factor-mediated signaling pathway Research
Researchers studying negative regulation of tumor necrosis factor-mediated signaling pathway-related genes often need to determine whether a candidate gene is causally involved in dampening TNF signaling or is merely a bystander. EDITGENE provides the CRISPR tools and services to answer these questions with precision.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of tumor necrosis factor-mediated signaling pathway research.
Frequently Asked Questions About negative regulation of tumor necrosis factor-mediated signaling pathway
What is GO:0010804?
GO:0010804 is the Gene Ontology term for negative regulation of tumor necrosis factor-mediated signaling pathway, describing any process that decreases the rate or extent of TNF signaling.
What genes are involved in negative regulation of TNF signaling?
Key genes include SHP-1 (PTPN6), DUSP4, PTEN, RCAN1, and components of the NF-kB and MAPK pathways.
How does SHP-1 negatively regulate TNF signaling?
SHP-1 activation by TNF-alpha inhibits growth factor-mediated cell proliferation in endothelial cells, dampening the pathway.
What is the role of DUSP4 in TNF signaling?
DUSP4 is suppressed by TNF-alpha and modulates crosstalk between NF-kB and MAPK, affecting endothelial cell survival.
How is PTEN linked to TNF signaling?
PTEN modulates VEGF-mediated signaling and angiogenic effects, which intersect with TNF survival pathways.
What diseases are associated with dysregulated TNF negative regulation?
Inflammatory diseases, cancer, steroid-induced necrosis of the femoral head, and endotoxic shock.
What experimental models are used to study GO:0010804?
CRISPR knockout, point mutation, knock-in, overexpression, RNA-seq, proteomics, and pharmacological assays.
Can CRISPR be used to study negative regulation of TNF signaling?
Yes, CRISPR knockout and knock-in models are powerful tools to dissect gene function in this pathway.
What is the connection between TNF signaling and mast cells?
Calcineurin-Rcan1 interaction contributes to mast cell activation, which can influence TNF production and signaling.
How can phenylmethimazole affect TNF signaling?
Phenylmethimazole inhibits proinflammatory mediators and is protective in endotoxic shock, likely by enhancing negative regulation.
Conclusion
GO:0010804, negative regulation of tumor necrosis factor-mediated signaling pathway, is a critical biological process that prevents excessive inflammation and tissue damage. Key regulators such as SHP-1, DUSP4, and PTEN provide multiple layers of control over TNF-induced NF-kB and MAPK activation. Dysregulation of this process contributes to inflammatory diseases, cancer, and bone necrosis, making it a promising therapeutic target. Advances in CRISPR-based models and bioinformatics will continue to uncover new players and mechanisms, offering opportunities for drug discovery and precision medicine.
References
- 1. Kishore R et al.. 2003. Tumor necrosis factor-mediated E2F1 suppression in endothelial cells: differential requirement of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signal transduction pathways.. Circ Res 93(10):932-40 PMID: 14576193
- 2. Kao DD et al.. 2013. Tumor necrosis factor-α-mediated suppression of dual-specificity phosphatase 4: crosstalk between NFκB and MAPK regulates endothelial cell survival.. Mol Cell Biochem 382(1-2):153-62 PMID: 23812841
- 3. Nakagami H et al.. 2002. Tumor necrosis factor-alpha inhibits growth factor-mediated cell proliferation through SHP-1 activation in endothelial cells.. Arterioscler Thromb Vasc Biol 22(2):238-42 PMID: 11834522
- 4. Huang J et al.. 2002. PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects.. J Biol Chem 277(13):10760-6 PMID: 11784722
- 5. Ren G et al.. 2024. Differential Gene Expression and Immune Cell Infiltration in Patients with Steroid-induced Necrosis of the Femoral Head.. Endocr Metab Immune Disord Drug Targets 24(12):1377-1394 PMID: 38204239
- 6. Wu Z et al.. 2013. Calcineurin-Rcan1 interaction contributes to stem cell factor-mediated mast cell activation.. J Immunol 191(12):5885-94 PMID: 24218457
- 7. Amaro A et al.. 2013. Evidence of epidermal growth factor receptor expression in uveal melanoma: inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity.. Eur J Cancer 49(15):3353-65 PMID: 23849826
- 8. Benavides U et al.. 2012. Phenylmethimazole inhibits production of proinflammatory mediators and is protective in an experimental model of endotoxic shock*.. Crit Care Med 40(3):886-94 PMID: 22020240
